U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Monday.

Shares of Norwegian Cruise Line Holdings Ltd (NYSE:NCLH) fell in pre-market trading following first-quarter results.

Norwegian Cruise Line reported quarterly earnings of 23 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $2.331 billion which missed the analyst consensus estimate of $2.357 billion.

The company also cut its FY2026 adjusted EPS guidance from $2.38 to $1.45-$1.79.

Norwegian Cruise Line shares dipped 4.9% to $17.89 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• Xanadu Quantum Technologies (NASDAQ:XNDU) shares dipped 66.9% to $11.97 in pre-market trading. Xanadu will report first quarter financial results on May 14.
• Tuniu Corp (NASDAQ:TOUR) fell 14.2% to $6.10 in pre-market trading.
• Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares tumbled 7.4% to $31.50 in pre-market trading after surging 89% on Friday. Hemab Therapeutics priced its upsized initial public offering of 16.75 million common shares at $18.00 per share.
• Nextdoor Holdings Inc (NYSE:NXDR) fell 7.3% to $1.53 in pre-market trading.
• Evolus Inc (NASDAQ:EOLS) fell 6.2% to $5.00 in pre-market trading. Evolus will report first quarter financial results on May 4.
• Valneva SE (NASDAQ:VALN) declined 6.2% to $5.02 in pre-market trading.
• Aura Biosciences Inc (NASDAQ:AURA) fell 5.8% to $6.60 in pre-market trading after the company announced a proposed public offering of common stock and pre-funded warrants. The company also named Natalie Holles as new CEO.
• Enovis Corp (NYSE:ENOV) declined 5.7% to $22.27 in pre-market trading.
• Spyre Therapeutics Inc (NASDAQ:SYRE) dipped 5.4% to $65.70 in pre-market trading. Spyre Therapeutics announced grants of inducement awards.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.